$JNJ News
Last published 1d ago
- 1d agoJNJJohnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 StudyPR NewswireJohnson & Johnson (NYSE: JNJ) today announced that Study 452, the second pivotal Phase 3 study evaluating CAPLYTA (lumateperone) for the...
- 2d agoJNJVRTXHUMEW+1Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open EnrollmentPR NewswireMarket Updates News Commentary - Health care stocks moved higher with the broader market on Monday morning. As of 9:58 a.m. ET, the State...
- 3d agoJNJJohnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancerPR NewswireFirst-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using...
- 4d agoJNJJohnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patientsPR NewswireJohnson & Johnson (NYSE: JNJ) today announced new patient experience findingsa from the Phase 2 DAHLIAS study of nipocalimab in Sjögren's...
- 4d agoJNJJohnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptidePR NewswireJohnson & Johnson (NYSE: JNJ) today announced positive results from a Phase 3 study investigating ICOTYDE® (icotrokinra) in biologic-naïve...
- 5d agoAAPLNVDAIBMJNJ+4U.S. Reshoring and Nearshoring: A Sustainable Economic TailwindStifel InsightsMarket Sight | Lines Investors are increasingly worried about market levels and the possibility of an artificial intelligence (AI) “bubble.” Despite the worries, however, during earnings calls and elsewhere, executives are highlighting a powerful, long-term positive theme: making more in America. What began as a reaction to pandemic-era disruptions has evolved into a structural reindustrializatio ...
- 1w agoGMABABBVMRKJNJ+4A little-known biotech’s high-stakes cancer bet just paid off and its shares doubledCNBCGenmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
- 2w agoJNJJohnson & Johnson to Host Enterprise Business ReviewBusiness WireJohnson & Johnson (NYSE:JNJ) will hold an Enterprise Business Review for the investment community on Tuesday, December 8th, 2026. During the event, Company leaders will provide a detailed review of the Innovative
- 2w agoJNJRYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancerPR NewswireResponses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 studyData highlight the role of
- 2w agoJNJJohnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ moleculePR NewswireJNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed tumor-selective protein
- 2w agoJNJJohnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancerPR NewswireNew substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgeryTwice as many patients remained free from subsequent
- 2w agoJNJJohnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026Business WireVARIPURE findings reported 100% acute procedural success with the VARIPULSE Pro Platform, 0.4% primary adverse event rate and a mean ablation time of 17.9 minutesi Omny-IRE data showed 82.5% of patients treated with
- 3w agoPLNTDISNFLXAAPL+4Stifel BitsStifel Insights2%: The increase in overall median net worth between 2022 and 2025, according to a Federal Reserve study.4,400-4,700 years: The estimated age of a shipwreck discovered off the coast of Türkiye, which archaeologists say is the world’s oldest.
- 3w agoJNJJohnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in HalfBusiness WireNext-generation intravascular lithotripsy (IVL) catheter delivers pulses at 2 Hz, improving efficiency in calcium modification treatment of coronary artery disease1 Faster pulsing reduces duration patients may
- 3w agoJNJJohnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistulaPR NewswireTREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose groupThese findings build on the Phase
- 4w agoJNJJohnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026Business WireJohnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on
- 4w agoJNJJohnson & Johnson reports Q3 2026 results, raises 2026 guidanceBusiness Wire2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational growth of 6.0%* and adjusted operational growth of 6.1%* 2026 Third-Quarter earnings per share (EPS) of $0.09 reflects a one-time
- 1mo agoJNJTREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's diseasePR NewswireNew long-term data showed clinical remission rates of up to 94% and endoscopic remission rates of up to 61% in adults with moderately to severely active Crohn's disease 88% of patients achieved 90-day
- 1mo agoJNJNew TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroupsPR NewswireNew prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposureFindings build on first positive results where TREMFYA
- 1mo agoPEPDALHUMJNJ+1After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings ReportsPR NewswireVANCOUVER, BC, Oct. 12, 2026 /PRNewswire/ -- American News Group News Commentary - The S&P 500 set an all-time high on Tuesday, October 6, and finished the week at 7,811.54 after a Friday gain of 0.6%, with the Dow
- 1mo agoTSMGSWFCJPM+9Cramer’s week ahead: Earnings kick off as banks and chipmakers face big testsCNBCCNBC’s Jim Cramer said next week’s earnings reports will give investors a clearer picture of corporate performance and the strength of the AI trade.
- 1mo agoJNJNew Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasisPR NewswirePhase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost clear skin at two years and a continued favorable
- 1mo agoNTHIMRNAMRKJNJ2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New HopeGlobeNewswireDENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) -- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time? A series of
- 1mo agoJNJJohnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapyPR NewswireJohnson & Johnson (NYSE: JNJ) today announced new two-year data from the Phase 3 ICONIC-TOTALa study demonstrating the positive impact of ICOTYDE®...
- 1mo agoJNJNew Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with MenopauseBusiness WireJohnson & Johnson, Naomi Watts and the American Optometric Association encourage women to make eye health part of midlife care Johnson & Johnson (NYSE:JNJ) today released new findings that show most women
- 1mo agoJNJJohnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)PR NewswireJohnson & Johnson (NYSE: JNJ) today announced new findings on IMAAVY® (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG)...
- 1mo agoJNJJohnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) studyPR NewswireJohnson & Johnson (NYSE: JNJ) today announced that TREMFYA® (guselkumab) met the primary and major secondary endpoints demonstrating both improvement ...
- 1mo agoJNJSingle infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myelomaPR NewswireJohnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, announced today new long-term follow-up data from the initial...
- 1mo agoJNJNew model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myelomaPR NewswireJohnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-3 study showing...
- 1mo agoJNJDePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026Business WireNew innovations across fracture fixation, connected care, AI-assisted surgery and procedural solutions reinforce the company's leadership in trauma care. DePuy Synthes, a global leader in orthopaedic technologies
- 1mo agoJNJCAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 studyPR NewswireJohnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 study evaluating CAPLYTA® (lumateperone) for the...
- 1mo agoJNJJOHJOHDeutsche Bank Healthcare Summit - JOHNSON & JOHNSONEarnings Call TranscriptsGood afternoon, everybody. My name is Andrew Calloway. I'm responsible for healthcare investment banking here at Deutsche Bank. I've joined by my partner, John Guskin, who's responsible for our medtech effort. And we are
- 1mo agoJNJJOHJOHJNJ - 1774424 - JOHNSON & JOHNSONEarnings Call TranscriptsGood afternoon, everybody. My name is Andrew Calloway. I'm responsible for healthcare investment banking here at Deutsche Bank. I've joined by my partner, John Guskin, who's responsible for our medtech effort. And we are
- 1mo agoJNJRYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026PR NewswireJohnson & Johnson (NYSE:JNJ) today announced new results from the Phase 2b COPERNICUS study evaluating how subcutaneous RYBREVANT FASPRO (amivantamab ...
- 1mo agoJNJJohnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancerPR NewswireJohnson & Johnson (NYSE: JNJ) today announced results from the final overall survival (OS) analysis of the Phase 3 PAPILLON study evaluating...
- 2mo agoJNJJohnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact LensesBusiness WireNew 2-week reusable contact lens brings advanced ACUVUE OASYS MAX technologies to deliver superior comfort and visual clarity to patients, even at day 14*†1 Expands the ACUVUE OASYS MAX portfolio with an advanced
- 2mo agoJNJJohnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026PR NewswireJohnson & Johnson (NYSE: JNJ) today announced that 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio...
- 2mo agoJNJJohnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare SummitBusiness WireJohnson & Johnson (NYSE:JNJ) will present at the Deutsche Bank 2026 Healthcare Summit on Thursday, September 17th, 2026. Management will participate in a Fireside Chat at 12:00 p.m. Eastern Time. A live audio
- 2mo agoJNJJohnson & Johnson to Host Investor Conference Call on Third-Quarter ResultsBusiness WireJohnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer,
- 2mo agoJNJFDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patientsPR NewswireJohnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) approval of IMAAVY® (nipocalimab-aahu) for the treatment of ...
- 3mo agoJNJJohnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceBusiness WireJohnson & Johnson (NYSE:JNJ) will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14th, 2026. Management will participate in a Fireside Chat at 11:30 a.m. Eastern
- 3mo agoCOFAXPRLWSM+9Jim Cramer highlights 5 investing themes — and the stocks to buy for eachCNBCCNBC’s Jim Cramer said earnings season reinforced five investing themes he thinks will produce the market's best buying opportunities.
- 3mo agoHELPDFTXCMPSJNJ+1A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 ReadoutGlobeNewswireNEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - In biotech, the gap between a promising drug and a commercial success is often bridged by a single thing: the operator who has done it
- 3mo agoGOOGLJNJStifel BitsStifel InsightsEvery summer we hand our incoming interns a pencil and a survey (just kidding, it’s just a survey link) and ask how the next generation spends, saves, and sees the world. Think of it as a sneak peek at tomorrow’s consumer.So, here are some of the results.Start with the wallet. Cash is practically extinct, and most would rather tap a phone than swipe a card. Yet this same crowd that lives on its de ...
- 3mo agoJNJJohnson & Johnson to Participate in the 2026 Wells Fargo Healthcare ConferenceBusiness WireJohnson & Johnson (NYSE:JNJ) will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9th, 2026. Management will participate in a Fireside Chat at 11:00 a.m. Eastern Time. A live audio
- 3mo agoABBVJNJINMDANIK+1Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next OneGlobeNewswireNEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- American News Group News Commentary - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator
- 3mo agoJNJJohnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective SeptemberBusiness WireJohnson & Johnson (NYSE:JNJ) today announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine following a distinguished career and over
- 3mo agoJNJJohnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancerPR NewswireJohnson & Johnson (NYSE:JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental...
- 3mo agoJNJJohnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology InnovationBusiness WireBroadens capabilities in targeting pan-KRAS and other drivers of hard-to-treat cancers Adds novel degrader antibody conjugate platform designed to address key limitations of existing therapies Advances
- 3mo agoJNJJohnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune ResetBusiness WireAdvances differentiated immunology program with the potential to address significant unmet need in immune-mediated disease Novel in vivo CAR-T platform is designed to generate CAR-T therapies directly within the